You are here
Current Challenges, New Insights and Future Directions: challenging CD30+ lymphomas
Prof. Illidge, Prof. Gisselbrecht, and Prof. Borchmann discussed the context and biology of CD30 and the rationale for CD30-targeting therapy. They also introduced the mechanism of action of brentuximab vedotin.
Prof. Borchmann presented an HL patient case and discussed the different treatment strategies with Prof. Gisselbrecht and Prof. Zinzani.
Prof. Gisselbrecht explained that most patients with relapsed peripheral T-cell lymphoma (PTCL) have poor outcomes.
Prof. d’Amore explained the general strategy for PTCL treatment in Europe, and he discussed a recent trial of brentuximab vedotin in CD30+ non-Hodgkin lymphoma (NHL).
Subscribe to our E-Alert to keep up to date with new webcast content published to the site.